Transaction Overview - Royalty Pharma closed a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash, resulting in total cash proceeds of $530 million on the original $300 million investment made in September 2022 [1] - The company achieved an attractive return by monetizing future fixed payments at a low discount rate of 5.35% and plans to redeploy the proceeds into higher-returning investment opportunities, including share repurchases and acquiring new royalties [1][8] Strategic Context - The monetization was driven by Novartis' acquisition of MorphoSys, which created a unique opportunity to convert fixed long-term payments into a large cash inflow at an attractive return for shareholders [2] - Royalty Pharma updated its capital allocation framework earlier in the year, aiming to generate attractive returns through a blend of royalty investments and share repurchases, enhancing flexibility for disciplined capital allocation [2] Transaction Details - Royalty Pharma entered a long-term strategic funding partnership with MorphoSys in 2021, providing up to $2.025 billion for MorphoSys' acquisition of Constellation Pharmaceuticals, acquiring royalties on Tremfya and other development-stage assets [3] - Prior to the monetization, Royalty Pharma received two quarterly repayments on the Development Funding Bonds, totaling $19.4 million ($9.7 million in Q4 2024 and $9.7 million in January 2025), which will be recorded in Portfolio Receipts [4] - The $511 million monetization proceeds will be treated as an asset sale and not recorded as Portfolio Receipts, and Royalty Pharma will no longer receive Development Funding Bond payments after this transaction [4] Company Background - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, collaborating with academic institutions, research hospitals, and companies of all sizes [6] - The company's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and Johnson & Johnson's Tremfya, as well as 14 development-stage product candidates [6] Financial Impact - The total proceeds of $530 million on the original $300 million investment strengthen the company's balance sheet and provide added flexibility to pursue its disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions [8]

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call informa ...

Core Viewpoint - Royalty Pharma (RPRX) shares have increased by 23.4% in the past four weeks, closing at $30.75, with a mean price target of $40.33 indicating a potential upside of 31.2% [1] Price Targets - The average price target consists of six estimates ranging from a low of $28 to a high of $51, with a standard deviation of $7.39, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential decline of 8.9%, while the highest suggests a 65.9% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [7] Analyst Insights - Analysts have shown strong agreement in revising earnings estimates upward, which supports the expectation of a stock price increase [4][9] - The Zacks Consensus Estimate for the current year has increased by 2.3% due to one upward revision and no negative revisions in the last 30 days [10] - RPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [5][6] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [8]

Stock Performance - Royalty Pharma plc (NASDAQ: RPRX) stock price increased by more than 16% following a Strong Buy suggestion in early November 2024, outperforming the S&P 500 change [1] Analyst Position - The analyst has a beneficial long position in RPRX shares through stock ownership, options, or other derivatives [2] Disclosure Information - The article expresses the analyst's own opinions and is not receiving compensation other than from Seeking Alpha [2] - Seeking Alpha's analysts are third-party authors, including both professional and individual investors, who may not be licensed or certified by any institute or regulatory body [3]

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, suggesting a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support or ...

Exhibit 99.1 ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NEW YORK, NY, January 10, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held a ...

Core Insights - Royalty Pharma expects Portfolio Receipts for 2024 to reach approximately $2.8 billion, reflecting a year-over-year growth of about 13% in Royalty Receipts [2][3][7] - The company has deployed around $2.8 billion in capital for royalty transactions in 2024, marking a record year for synthetic royalty deals [2][5] - Royalty Pharma's development-stage pipeline has the potential to generate over $1 billion in new royalties from innovative therapies across various therapeutic categories [2][8] Financial Performance - Preliminary unaudited results indicate that Royalty Pharma anticipates adjusted EBITDA for 2024 to be between $2,560 million and $2,570 million, with Portfolio Cash Flow expected to be approximately $2,450 million to $2,455 million [3][26] - Net cash provided by operating activities is projected to be around $2,760 million to $2,770 million for the full year 2024 [3][26] Capital Deployment and Pipeline - Since 2020, Royalty Pharma has announced transactions totaling approximately $15.5 billion, with significant additions in 2024 including royalties on Voranigo and frexalimab [5][8] - The company is set to benefit from several new product launches in 2025, including Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy [6][7] Upcoming Events - Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 6:45 p.m. ET [9]

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intend ...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intend ...

Group 1: W.P. Carey - W.P. Carey is a real estate investment trust (REIT) trading approximately 35% below its 2022 peak, currently offering a 6.2% yield [3][5] - The REIT has a 98.8% occupancy rate after spinning off 59 buildings into another company, which has allowed it to focus on its remaining properties [3][6] - W.P. Carey has raised its dividend payout three times since the spinoff and expects adjusted funds from operations to be between $4.65 and $4.71 per share this year, significantly above its current dividend obligation of $3.50 annually [5][6] - The REIT owns 1,430 single-tenant buildings across Europe and North America, with a well-diversified tenant list [6][7] Group 2: Royalty Pharma - Royalty Pharma offers a 3.2% yield and invests in drugmakers in exchange for royalty stakes in their products, benefiting from the reliable trend of increasing prescription drug expenses [8][9] - The company has a stake in 15 blockbuster drugs generating over $1 billion in annual sales and has raised its dividend four times since going public in 2020, totaling a 40% increase [9][10] - Royalty Pharma has announced transactions worth $10.1 billion since the start of 2022, with expectations for significant earnings growth in the coming years [10][11] - The company is positioned to capitalize on the need for over $1 trillion in capital for startup drugmakers over the next decade, making it a leading provider of royalty financing [11]